Evan is a highly regarded IP trial attorney and advisor known for his successful representation of clients in high-stakes intellectual property and contractual disputes in the United States and in international jurisdictions. He has a strong record of wins in cases to protect products with hundreds of millions or billions of dollars in revenue, and in defending clients in disputes involving alleged damages of hundreds of millions of dollars. Leveraging his research experience in chemistry and biochemistry, Evan represents companies and academic institutions across the pharmaceutical, biotechnology, medical devices, chemical, and cannabis fields.

A significant portion of Evan’s practice involves representing clients in patent disputes in US federal district courts, before the Patent Trial and Appeal Board, and at the US Court of Appeals for the Federal Circuit. He also litigates complex contract and licensing disputes involving multi-national forum litigation and international arbitration components. As a go-to advisor for strategic IP counseling and early dispute services, Evan also regularly takes a leading role in pre-litigation preparation and negotiations of favorable licensing deals, helping clients achieve their business goals.

In addition, Evan represents life sciences companies in matters involving the intersection of US Food & Drug Administration (FDA) regulations and US patent rights, including through trial and appeal in Hatch-Waxman and the Biologics Price Competition and Innovation Act (BPCIA) disputes. He is also called on to provide strategic advice on a broad range of related FDA matters.

Evan has achieved international recognition for his work, including repeated listings in the IAM Patent 1000: The World’s Leading Patent Professionals guide. He is also a respected thought leader who speaks and writes on new developments involving the life sciences industry and intellectual property law in the US and globally and provides commentary to legal and industry publications.

Prior to joining Mintz, Evan was a partner at an international law firm, where he achieved a no-loss record in representing life sciences clients and others in patent litigations and other disputes. While earning his master’s degree in chemistry, he conducted research focused on the characterization of protein-protein interactions, including for RNA splicing machinery utilized in connection with the treatment of spinal muscular atrophy (SMA).